Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 154 entries
Sorted by: Best Match Show Resources per page
Chile: elect a president to strengthen climate action, not weaken it.

Nature

Rojas M, Muñoz JC, Palma-Behnke R, Marquet PA, Stehr A, González H.
PMID: 34893767
Nature. 2021 Dec;600(7889):386. doi: 10.1038/d41586-021-03662-5.

No abstract available.

Cite
Rojas M, Muñoz JC, Palma-Behnke R, et al. Chile: elect a president to strengthen climate action, not weaken it. Nature. 2021;600(7889):386doi: 10.1038/d41586-021-03662-5.
Rojas, M., Muñoz, J. C., Palma-Behnke, R., Marquet, P. A., Stehr, A., & González, H. (2021). Chile: elect a president to strengthen climate action, not weaken it. Nature, 600(7889), 386. https://doi.org/10.1038/d41586-021-03662-5
Rojas, Maisa, et al. "Chile: elect a president to strengthen climate action, not weaken it." Nature vol. 600,7889 (2021): 386. doi: https://doi.org/10.1038/d41586-021-03662-5
Rojas M, Muñoz JC, Palma-Behnke R, Marquet PA, Stehr A, González H. Chile: elect a president to strengthen climate action, not weaken it. Nature. 2021 Dec;600(7889):386. doi: 10.1038/d41586-021-03662-5. PMID: 34893767.
Copy Download .nbib Format: NLM
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.

Clinical cancer research : an official journal of the American Association for Cancer Research

Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, Jendrisak A, Berry WR, Gupta S, Gregory SG, Wenstrup R, Antonarakis ES, George DJ, Scher HI, Armstrong AJ.
PMID: 33820782
Clin Cancer Res. 2021 Jul 15;27(14):4077-4088. doi: 10.1158/1078-0432.CCR-20-3471. Epub 2021 Apr 05.

PURPOSE: While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for a minority of this resistance. Neuroendocrine (NE) differentiation...

Cite
Brown LC, Halabi S, Schonhoft JD, et al. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021;27(14):4077-4088doi: 10.1158/1078-0432.CCR-20-3471.
Brown, L. C., Halabi, S., Schonhoft, J. D., Yang, Q., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Barnett, E. S., Carbone, E. A., Zhao, J. L., Healy, P., Anand, M., Gill, A., Jendrisak, A., Berry, W. R., Gupta, S., Gregory, S. G., Wenstrup, R., Antonarakis, E. S., George, D. J., Scher, H. I., & Armstrong, A. J. (2021). Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 4077-4088. https://doi.org/10.1158/1078-0432.CCR-20-3471
Brown, Landon C, et al. "Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 4077-4088. doi: https://doi.org/10.1158/1078-0432.CCR-20-3471
Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, Jendrisak A, Berry WR, Gupta S, Gregory SG, Wenstrup R, Antonarakis ES, George DJ, Scher HI, Armstrong AJ. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 Jul 15;27(14):4077-4088. doi: 10.1158/1078-0432.CCR-20-3471. Epub 2021 Apr 05. PMID: 33820782; PMCID: PMC8282682.
Copy Download .nbib Format: NLM
Antibacterial Mechanism of Long-Chain Polyphosphates in Staphylococcus aureus.

Journal of food protection

Lee RM, Hartman PA, Stahr HM, Olson DG, Williams FD.
PMID: 31113131
J Food Prot. 1994 Apr;57(4):289-294. doi: 10.4315/0362-028X-57.4.289.

The results of previous studies indicated that the antibacterial effects of long-chain polyphosphates (sodium polyphosphate glassy [SPG] and sodium ultraphosphate [UP]) to Staphylococcus aureus ISP40 8325 could be attributed to damage to the cell envelope (cell wall or cell...

Cite
Lee RM, Hartman PA, Stahr HM, et al. Antibacterial Mechanism of Long-Chain Polyphosphates in Staphylococcus aureus. J Food Prot. 1994;57(4):289-294doi: 10.4315/0362-028X-57.4.289.
Lee, R. M., Hartman, P. A., Stahr, H. M., Olson, D. G., & Williams, F. D. (1994). Antibacterial Mechanism of Long-Chain Polyphosphates in Staphylococcus aureus. Journal of food protection, 57(4), 289-294. https://doi.org/10.4315/0362-028X-57.4.289
Lee, Ruby M, et al. "Antibacterial Mechanism of Long-Chain Polyphosphates in Staphylococcus aureus." Journal of food protection vol. 57,4 (1994): 289-294. doi: https://doi.org/10.4315/0362-028X-57.4.289
Lee RM, Hartman PA, Stahr HM, Olson DG, Williams FD. Antibacterial Mechanism of Long-Chain Polyphosphates in Staphylococcus aureus. J Food Prot. 1994 Apr;57(4):289-294. doi: 10.4315/0362-028X-57.4.289. PMID: 31113131.
Copy Download .nbib Format: NLM
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Frontiers in pharmacology

Barratt SL, Mulholland S, Al Jbour K, Steer H, Gutsche M, Foley N, Srivastava R, Sharp C, Adamali HI.
PMID: 30618768
Front Pharmacol. 2018 Dec 17;9:1480. doi: 10.3389/fphar.2018.01480. eCollection 2018.

No abstract available.

Cite
Barratt SL, Mulholland S, Al Jbour K, et al. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Front Pharmacol. 2018;9:1480doi: 10.3389/fphar.2018.01480.
Barratt, S. L., Mulholland, S., Al Jbour, K., Steer, H., Gutsche, M., Foley, N., Srivastava, R., Sharp, C., & Adamali, H. I. (2018). South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Frontiers in pharmacology, 91480. https://doi.org/10.3389/fphar.2018.01480
Barratt, Shaney L, et al. "South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)." Frontiers in pharmacology vol. 9 (2018): 1480. doi: https://doi.org/10.3389/fphar.2018.01480
Barratt SL, Mulholland S, Al Jbour K, Steer H, Gutsche M, Foley N, Srivastava R, Sharp C, Adamali HI. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Front Pharmacol. 2018 Dec 17;9:1480. doi: 10.3389/fphar.2018.01480. eCollection 2018. PMID: 30618768; PMCID: PMC6304353.
Copy Download .nbib Format: NLM
Cross-Flow Filtration of .

Micromachines

Busche JF, Möller S, Stehr M, Dietzel A.
PMID: 31614761
Micromachines (Basel). 2019 Oct 12;10(10). doi: 10.3390/mi10100691.

Infections with antimicrobial-resistant (AMR) bacteria are globally on the rise. In the future, multi-resistant infections will become one of the major problems in global health care. In order to enable reserve antibiotics to retain their effect as long as...

Cite
Busche JF, Möller S, Stehr M, et al. Cross-Flow Filtration of . Micromachines (Basel). 2019;10(10)doi: 10.3390/mi10100691.
Busche, J. F., Möller, S., Stehr, M., & Dietzel, A. (2019). Cross-Flow Filtration of . Micromachines, 10(10), . https://doi.org/10.3390/mi10100691
Busche, Jan F, et al. "Cross-Flow Filtration of ." Micromachines vol. 10,10 (2019). doi: https://doi.org/10.3390/mi10100691
Busche JF, Möller S, Stehr M, Dietzel A. Cross-Flow Filtration of . Micromachines (Basel). 2019 Oct 12;10(10). doi: 10.3390/mi10100691. PMID: 31614761; PMCID: PMC6843207.
Copy Download .nbib Format: NLM
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.

JCO precision oncology

Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W.
PMID: 32856010
JCO Precis Oncol. 2020;4:355-366. doi: 10.1200/po.19.00346. Epub 2020 Apr 16.

PURPOSE: Alterations in DNA damage repair (DDR) genes occur in up to 25% of patients with metastatic castration-resistant prostate cancer (mCRPC) and may sensitize to platinum chemotherapy. We aimed to evaluate the efficacy of platinum-based chemotherapy in DDR-mutant (DDRmut)...

Cite
Mota JM, Barnett E, Nauseef JT, et al. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precis Oncol. 2020;4:355-366doi: 10.1200/po.19.00346.
Mota, J. M., Barnett, E., Nauseef, J. T., Nguyen, B., Stopsack, K. H., Wibmer, A., Flynn, J. R., Heller, G., Danila, D. C., Rathkopf, D., Slovin, S., Kantoff, P. W., Scher, H. I., Morris, M. J., Schultz, N., Solit, D. B., & Abida, W. (2020). Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO precision oncology, 4355-366. https://doi.org/10.1200/po.19.00346
Mota, Jose Mauricio, et al. "Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations." JCO precision oncology vol. 4 (2020): 355-366. doi: https://doi.org/10.1200/po.19.00346
Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precis Oncol. 2020;4:355-366. doi: 10.1200/po.19.00346. Epub 2020 Apr 16. PMID: 32856010; PMCID: PMC7446522.
Copy Download .nbib Format: NLM
Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions.

Genes

Brandl C, Schulz HL, Charbel Issa P, Birtel J, Bergholz R, Lange C, Dahlke C, Zobor D, Weber BHF, Stöhr H.
PMID: 28644393
Genes (Basel). 2017 Jun 23;8(7). doi: 10.3390/genes8070170.

A significant portion of patients diagnosed with vitelliform macular dystrophy (VMD) do not carry causative mutations in the classic VMD genes

Cite
Brandl C, Schulz HL, Charbel Issa P, et al. Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions. Genes (Basel). 2017;8(7)doi: 10.3390/genes8070170.
Brandl, C., Schulz, H. L., Charbel Issa, P., Birtel, J., Bergholz, R., Lange, C., Dahlke, C., Zobor, D., Weber, B. H. F., & Stöhr, H. (2017). Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions. Genes, 8(7), . https://doi.org/10.3390/genes8070170
Brandl, Caroline, et al. "Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions." Genes vol. 8,7 (2017). doi: https://doi.org/10.3390/genes8070170
Brandl C, Schulz HL, Charbel Issa P, Birtel J, Bergholz R, Lange C, Dahlke C, Zobor D, Weber BHF, Stöhr H. Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions. Genes (Basel). 2017 Jun 23;8(7). doi: 10.3390/genes8070170. PMID: 28644393; PMCID: PMC5541303.
Copy Download .nbib Format: NLM
Akrinor.

Frontiers in pharmacology

Kloth B, Pecha S, Moritz E, Schneeberger Y, Söhren KD, Schwedhelm E, Reichenspurner H, Eschenhagen T, Böger RH, Christ T, Stehr SN.
PMID: 28588484
Front Pharmacol. 2017 May 23;8:272. doi: 10.3389/fphar.2017.00272. eCollection 2017.

No abstract available.

Cite
Kloth B, Pecha S, Moritz E, et al. Akrinor. Front Pharmacol. 2017;8:272doi: 10.3389/fphar.2017.00272.
Kloth, B., Pecha, S., Moritz, E., Schneeberger, Y., Söhren, K. D., Schwedhelm, E., Reichenspurner, H., Eschenhagen, T., Böger, R. H., Christ, T., & Stehr, S. N. (2017). Akrinor. Frontiers in pharmacology, 8272. https://doi.org/10.3389/fphar.2017.00272
Kloth, Benjamin, et al. "Akrinor." Frontiers in pharmacology vol. 8 (2017): 272. doi: https://doi.org/10.3389/fphar.2017.00272
Kloth B, Pecha S, Moritz E, Schneeberger Y, Söhren KD, Schwedhelm E, Reichenspurner H, Eschenhagen T, Böger RH, Christ T, Stehr SN. Akrinor. Front Pharmacol. 2017 May 23;8:272. doi: 10.3389/fphar.2017.00272. eCollection 2017. PMID: 28588484; PMCID: PMC5441130.
Copy Download .nbib Format: NLM
Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

Nature reviews. Clinical oncology

Teo MY, O'Shaughnessy MJ, McBride SM, Vargas HA, Scher HI.
PMID: 29115302
Nat Rev Clin Oncol. 2018 Mar;15(3):150. doi: 10.1038/nrclinonc.2017.177. Epub 2017 Nov 08.

This corrects the article DOI: 10.1038/nrclinonc.2017.160.

Cite
Teo MY, O'Shaughnessy MJ, McBride SM, et al. Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nat Rev Clin Oncol. 2017;15(3):150doi: 10.1038/nrclinonc.2017.177.
Teo, M. Y., O'Shaughnessy, M. J., McBride, S. M., Vargas, H. A., & Scher, H. I. (2018). Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature reviews. Clinical oncology, 15(3), 150. https://doi.org/10.1038/nrclinonc.2017.177
Teo, Min Yuen, et al. "Drug development for noncastrate prostate cancer in a changed therapeutic landscape." Nature reviews. Clinical oncology vol. 15,3 (2018): 150. doi: https://doi.org/10.1038/nrclinonc.2017.177
Teo MY, O'Shaughnessy MJ, McBride SM, Vargas HA, Scher HI. Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nat Rev Clin Oncol. 2018 Mar;15(3):150. doi: 10.1038/nrclinonc.2017.177. Epub 2017 Nov 08. PMID: 29115302.
Copy Download .nbib Format: NLM
Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium.

Journal of intensive care

John M, Ely EW, Halfkann D, Schoen J, Sedemund-Adib B, Klotz S, Radtke F, Stehr S, Hueppe M.
PMID: 28560042
J Intensive Care. 2017 May 26;5:29. doi: 10.1186/s40560-017-0224-1. eCollection 2017.

BACKGROUND: Patients in intensive care units (ICU) are often diagnosed with postoperative delirium; the duration of which has a relevant negative impact on various clinical outcomes. Recent research found a potentially important role of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)...

Cite
John M, Ely EW, Halfkann D, et al. Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium. J Intensive Care. 2017;5:29doi: 10.1186/s40560-017-0224-1.
John, M., Ely, E. W., Halfkann, D., Schoen, J., Sedemund-Adib, B., Klotz, S., Radtke, F., Stehr, S., & Hueppe, M. (2017). Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium. Journal of intensive care, 529. https://doi.org/10.1186/s40560-017-0224-1
John, Mira, et al. "Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium." Journal of intensive care vol. 5 (2017): 29. doi: https://doi.org/10.1186/s40560-017-0224-1
John M, Ely EW, Halfkann D, Schoen J, Sedemund-Adib B, Klotz S, Radtke F, Stehr S, Hueppe M. Acetylcholinesterase and butyrylcholinesterase in cardiosurgical patients with postoperative delirium. J Intensive Care. 2017 May 26;5:29. doi: 10.1186/s40560-017-0224-1. eCollection 2017. PMID: 28560042; PMCID: PMC5446746.
Copy Download .nbib Format: NLM
Prostate cancer in 2011: Hitting old targets better and identifying new targets.

Nature reviews. Clinical oncology

Chen Y, Scher HI.
PMID: 22231760
Nat Rev Clin Oncol. 2012 Jan 10;9(2):70-2. doi: 10.1038/nrclinonc.2011.213.

Options to treat late-stage castration-resistant prostate cancer continued to increase in 2011, as three agents with different mechanisms of action prolonged life and a fourth reduced the morbidity of skeletal metastases. These outcomes contrasted with the heightened controversy generated...

Cite
Chen Y, Scher HI. Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat Rev Clin Oncol. 2012;9(2):70-2doi: 10.1038/nrclinonc.2011.213.
Chen, Y., & Scher, H. I. (2012). Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nature reviews. Clinical oncology, 9(2), 70-2. https://doi.org/10.1038/nrclinonc.2011.213
Chen, Yu, and Scher, Howard I. "Prostate cancer in 2011: Hitting old targets better and identifying new targets." Nature reviews. Clinical oncology vol. 9,2 (2012): 70-2. doi: https://doi.org/10.1038/nrclinonc.2011.213
Chen Y, Scher HI. Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat Rev Clin Oncol. 2012 Jan 10;9(2):70-2. doi: 10.1038/nrclinonc.2011.213. PMID: 22231760; PMCID: PMC5572096.
Copy Download .nbib Format: NLM
Laponite blue: dissolving the insoluble.

Angewandte Chemie (International ed. in English)

Lezhnina MM, Grewe T, Stoehr H, Kynast U.
PMID: 22952053
Angew Chem Int Ed Engl. 2012 Oct 15;51(42):10652-5. doi: 10.1002/anie.201203236. Epub 2012 Sep 05.

The neutral organic dye indigo forms an inorganic-organic hybrid material with nanoclays (see picture; blue circles on disks symbolizing indigo, spheres indicating liberated cations) and can thus be transferred into aqueous solution. Solids recovered from these solutions resemble the...

Cite
Lezhnina MM, Grewe T, Stoehr H, et al. Laponite blue: dissolving the insoluble. Angew Chem Int Ed Engl. 2012;51(42):10652-5doi: 10.1002/anie.201203236.
Lezhnina, M. M., Grewe, T., Stoehr, H., & Kynast, U. (2012). Laponite blue: dissolving the insoluble. Angewandte Chemie (International ed. in English), 51(42), 10652-5. https://doi.org/10.1002/anie.201203236
Lezhnina, Marina M, et al. "Laponite blue: dissolving the insoluble." Angewandte Chemie (International ed. in English) vol. 51,42 (2012): 10652-5. doi: https://doi.org/10.1002/anie.201203236
Lezhnina MM, Grewe T, Stoehr H, Kynast U. Laponite blue: dissolving the insoluble. Angew Chem Int Ed Engl. 2012 Oct 15;51(42):10652-5. doi: 10.1002/anie.201203236. Epub 2012 Sep 05. PMID: 22952053.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 154 entries